AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03219320
Drug: NYX-2925
RxNorm normalized name: NYX-2925
DrugBank: NYX-2925 (DB19149)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NYX-2925 is a novel small molecule that modulates the N-methyl-D-aspartate receptor (NMDAR).
Trial: NCT00749112
Drug: Alemtuzumab, Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Alemtuzumab 10 mg each 24 hrs subcutaneous for 3 days. Rituximab 100 mg IV every week for 4 weeks.
Trial: NCT03608358
Drug: Dapagliflozin 10 mg
RxNorm normalized name: dapagliflozin 10 MG
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 10 mg, oral tablet, once daily for 24 weeks of double-blind treatment period
Trial: NCT03608358
Drug: Dapagliflozin 5 mg
RxNorm normalized name: dapagliflozin 5 MG
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 5 mg, oral tablet, once daily for 24 weeks of double-blind treatment period
Trial: NCT03608358
Drug: Dapagliflozin 10 mg placebo to match
RxNorm normalized name: dapagliflozin 10 MG
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 10 mg, oral tablet, once daily for 24 weeks of double-blind treatment period
Trial: NCT03608358
Drug: Dapagliflozin 5 mg placebo to match
RxNorm normalized name: dapagliflozin 5 MG
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 5 mg, oral tablet, once daily for 24 weeks of double-blind treatment period
Trial: NCT03608358
Drug: Saxagliptin 5 mg
RxNorm normalized name: sAXagliptin 5 MG
DrugBank: Saxagliptin (DB06335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5 mg, oral tablet, once daily for 24 weeks of double-blinded treatment period, and for 16 weeks of open-label treatment period in Stratum A or 8 weeks of open-label treatment period in Stratum B
Trial: NCT03608358
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Stable dose of metformin immediate release/extended release (≥ 1500 mg/day or at a maximal tolerated dose) throughout the whole study period
Trial: NCT03752424
Drug: Silver nanoparticles
RxNorm normalized name: Silver nanoparticles
DrugBank: Silver (DB12965)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The active group will receive silver nanoparticles in different dosage forms as an anti-microbial drug.
Trial: NCT03752424
Drug: Topical approved anti-microbial gel
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The placebo group will receive topical FDA approved anti-microbial jel in different dosage forms as control drug.
Trial: NCT01431807
Drug: SYR-472
RxNorm normalized name: petrolatum 0.472 MG/MG
DrugBank: Petrolatum (DB11058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral, for up to 52 weeks.
Trial: NCT03255226
Drug: Tolvaptan
RxNorm normalized name: Tolvaptan
DrugBank: Tolvaptan (DB06212)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tolvaptan 1% granules or tolvaptan 15 mg tablet with water once daily.
Trial: NCT01099449
Drug: calcium gluconate
RxNorm normalized name: Calcium Gluconate
DrugBank: Calcium gluconate (DB11126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT01099449
Drug: magnesium sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium sulfate (DB00653)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01099449
Drug: oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04110535
Drug: Remimazolam
RxNorm normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: IV administration over 1 minute
Trial: NCT04110535
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV administration over 1 minute
Trial: NCT01017731
Drug: Moxifloxacin
RxNorm normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT01017731
Drug: Diphenhydramine
RxNorm normalized name: Diphenhydramine
DrugBank: Diphenhydramine (DB01075)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered IV
Trial: NCT03100786
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Active treatment with dexamethasone from randomisation (IV followed by oral according to disease severity at the start of treatment): Dexamethasone for intravenous injection and dexamethasone for oral ingestion
Trial: NCT00833391
Drug: open label
RxNorm normalized name: Ga-68-Labeled PSMA-11
DrugBank: Gallium Ga-68 gozetotide (DB16019)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is an open-label, randomized, single-dose, five-period, crossover study. All subjects will receive GSK1838262.
Trial: NCT01452100
Drug: prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients enrolled into the study will be treated with prednisone, 20 mg/day (if body weight \<70 kg ; or 25mg/d if body weight \>70 kg) for 1 month, then tapered to 12.5 mg/d (month 2) and 7.5 mg/d (month 3) and stop. In both groups, patients will be treated according to expert advice including use of statins (according to French Health Agency recommendation), a RAS inhibitor and supportive treatment (including nutrition, treatment of heart failure, and dialysis).
Trial: NCT02215980
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02215980
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01536392
Drug: Granisetron
RxNorm normalized name: Granisetron
DrugBank: Granisetron (DB00889)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 34.3 mg of granisetron formulated in a transdermal patch replaced every 7 days. At cycle 1, participants receive granisetron by vein prior to IV cisplatin and prior to administration of transdermal patch.
Trial: NCT01536392
Drug: Ondansetron
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 8 mg of ondansetron by mouth three times a day starting with cisplatin administration and continued for 72 hours after chemotherapy infusion.
Trial: NCT00934440
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: * First treatment: 10 milligram per kilograms (MG/KG) intravenously (IV) on Day 1every two weeks over 90 minutes.~* Second treatment: 10 MG/KG IV on Day 1 every two weeks over 60 minutes.~* Third and subsequent treatments: 10 MG/KG IV on Day 1 every two weeks over 30 minutes (minimum of two cycles).
Trial: NCT00934440
Drug: Azacitidine
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: * Dose level 1: 35 mg/m2/day for 7 days.~* Dose level 2: 55 mg/m2/day for 7 days.~* Dose level 3: 75 mg/m2/day for 7 days.~  * mg/m2/day = dose based on height and weight
Trial: NCT01748240
Drug: Azacitidine and oral vorinostat
RxNorm normalized name: Vorinostat
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: In patients still responding after six cycles, the drugs will continue to be supplied, and follow up until death or unacceptable tolerance will be continued in all patients.
Trial: NCT01590758
Drug: Topical pexiganan cream 0.8%
DrugBank: Pexiganan (DB16293)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14 days of treatment
Trial: NCT02717832
Drug: hyperinsulinemic-euglycemic clamp
RxNorm normalized name: CLAMP
DrugBank: SARS-CoV-2 Sclamp (DB15849)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01818752
Drug: Carfilzomib
RxNorm normalized name: Carfilzomib
DrugBank: Carfilzomib (DB08889)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carfilzomib was administered over 30 minutes on days 1, 2, 8, 9, 22, 23, 29, and 30 for nine 42-day cycles. Carfilzomib 20 mg/m² IV was administered on days 1 and 2 of cycle 1, followed by escalation to 36 mg/m² IV starting on day 8 of cycle 1.
Trial: NCT01818752
Drug: Bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bortezomib 1.3 mg/m² was administered as a bolus IV injection or as a subcutaneous injection (per investigator's choice, dose modification, or regulatory approval) on days 1, 4, 8, 11, 22, 25, 29, and 32 of cycles 1 to 4, and on days 1, 8, 22, and 29 of cycles 5 to 9.
Trial: NCT01818752
Drug: Melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Melphalan 9 mg/m² was taken orally on days 1 to 4 of all cycles.
Trial: NCT01818752
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisone 60 mg/m² was taken orally on days 1 to 4 of all cycles.
Trial: NCT00178113
Drug: - Lyc-O-Mato (dietary supplement, 30 mg lycopene/day)
RxNorm normalized name: Padimate O
DrugBank: Padimate O (DB11570)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00004005
Drug: irinotecan hydrochloride
RxNorm normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01324141
Drug: Tempol
RxNorm normalized name: Tempol
DrugBank: Tempol (DB12449)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tempol gel will be applied to the bilateral groins and the gluteal cleft, avoiding a 3 cm radius from the anal verge, immediately prior to each fraction of radiation therapy (RT).
Trial: NCT01324141
Drug: 5-Fluorouracil
RxNorm normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-FU will be delivered as 1000mg/m(2)/day as 96 hour continuous infusion beginning on day 1 and 29.
Trial: NCT01324141
Drug: Mitomycin-C
RxNorm normalized name: Mitomycin-C
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mitomycin-C (MMC) will be delivered at a dose of 10mg/m(2) on days 1 and 29
Trial: NCT00551473
Drug: Lavoltidine
RxNorm normalized name: Lavoltidine
DrugBank: Lavoltidine (DB12884)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02644616
Drug: tolvaptan+torasemide
RxNorm normalized name: Tolvaptan
DrugBank: Torasemide (DB00214)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: tolvaptan 15mg/d po(10 days) + torasemide 20mg/d iv
Trial: NCT02644616
Drug: placebo+torasemide
DrugBank: Torasemide (DB00214)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo 15mg/d po(10 days) +torasemide 20mg/d iv
Trial: NCT01755026
Drug: cefazolin
RxNorm normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 gram dose for pre-operative prophylaxis
Trial: NCT01755026
Drug: cefazolin
RxNorm normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4 gram dose for pre-operative prophylaxis
Trial: NCT01214395
Drug: 5% tea tree oil nasal ointment
DrugBank: Tea tree oil (DB11218)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: daily for 5 days then weekly for 6 months
Trial: NCT03291093
Drug: 18F-Flutemetamol PET/MRI
DrugBank: Flutemetamol (18F) (DB09151)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: All patients will undergo a PET/MRI of the carotids after 18F-Flutemetamol injection.
Trial: NCT00602927
Drug: Varenicline
RxNorm normalized name: Varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Day 1 - Day 3 0.5mg once daily Day 4 - Day 7 0.5mg twice daily Day 8 - Day 13 1.0mg twice daily
Trial: NCT00294086
Drug: valsartan 160 mg
RxNorm normalized name: valsartan 160 MG
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00294086
Drug: valsartan 160 mg BID
RxNorm normalized name: valsartan 160 MG
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT03229694
Drug: Tracleer 125Mg Tablet
RxNorm normalized name: Tracleer 125mg Tablet
DrugBank: Bosentan (DB00559)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tracleer was administered orally at two hours before surgery and six hours after surgery.
Trial: NCT02459288
Drug: Clopidogrel first
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: After randomization, 2 weeks Clopidogrel (Plavix) 75 mg QD will be given and then crossover with following 2 weeks Ticagrelor (Brilinta) 90 mg bd
Trial: NCT02459288
Drug: Ticagrelor first
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After randomization, 2 weeks Ticagrelor (Brilinta) 90 mg bd will be given then crossover with following 2 weeks Clopidogrel (Plavix) 75 mg QD
Trial: NCT02087007
Drug: Cilostazol
RxNorm normalized name: Cilostazol
DrugBank: Cilostazol (DB01166)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100mg oral tablets bid during 2 weeks after dosing of 50mg oral tablets bid during 2 weeks
Trial: NCT00611754
Drug: Oxaliplatin, 5-FU
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxaliplatin: 130 mg/m² in 500 mL of 5% glucose solution as a 2-hour intravenous (IV) infusion on Day 1 and repeated every 3 weeks; 5-FU: following oxaliplatin administration, 1000 mg/m²/day as a continuous IV infusion from Day 1 toDay 4, every 3 weeks.Dose adjustments were made if the patient experienced AEs.
Trial: NCT02215018
Drug: BI 44370 TA solution
RxNorm normalized name: BI 44370 TA
DrugBank: BI 44370 TA (DB16037)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02215018
Drug: BI 44370 TA tablet
RxNorm normalized name: BI 44370 TA
DrugBank: BI 44370 TA (DB16037)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00095147
Drug: Infliximab (INF) + MTX, DB
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Infliximab, IV Solution, Infusion, Depends on participant weight, Every 2 Months, 12 months.
Trial: NCT00225264
Drug: Pioglitazone
RxNorm normalized name: Pioglitazone
DrugBank: Pioglitazone (DB01132)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pioglitazone 15 mg titrated up to 45 mg, tablets, orally, once daily and glimepiride placebo-matching capsules, orally, once daily for up to 72 weeks.
Trial: NCT00225264
Drug: Glimepiride
RxNorm normalized name: Glimepiride
DrugBank: Glimepiride (DB00222)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pioglitazone placebo-matching tablets, orally, once daily and glimepiride 1 mg titrated up to 4 mg, capsules, orally, once daily for up to 72 weeks.
Trial: NCT03471624
Drug: Tenofovir Alafenamide
RxNorm normalized name: Tenofovir Alafenamide
DrugBank: Tenofovir alafenamide (DB09299)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tenofovir alafenamide (TAF) is a new formulation of tenofovir with higher intracellular active drug concentration allowing for dosing of only 25 mg once daily and thus can potentially lower the already low risk of renal toxicity and bone loss with tenofovir disoproxil fumarate (TDF).
Trial: NCT01306929
Drug: pridopidine
RxNorm normalized name: Pridopidine
DrugBank: Pridopidine (DB11947)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 45mg bid
Trial: NCT01624246
Drug: Ceftaroline fosamil/Avibactam (CXL)
DrugBank: Ceftaroline fosamil (DB06590)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV infusion of CXL (combination of ceftaroline fosamil \[600 mg\] plus avibactam \[600 mg\]) infused over 60 (± 5) minutes.
Trial: NCT00181597
Drug: Trilostane
RxNorm normalized name: TRILOSTANE
DrugBank: Trilostane (DB01108)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Taken orally once a day for three days then twice daily thereafter.
Trial: NCT03810872
Drug: Afatinib
RxNorm normalized name: Afatinib
DrugBank: Afatinib (DB08916)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Open label
Trial: NCT03810872
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel
Trial: NCT02777320
Drug: paracetamol
RxNorm normalized name: Paracetamol
DrugBank: Acetaminophen (DB00316)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1000 mg Paracetamol in 150 ml normal saline given as a slow intravenous infusion over 5 minutes (100 ml of saline is removed before the addition of the 100 ml paracetamol to be the same volume)
Trial: NCT00509665
Drug: gemcitabine hydrochloride
RxNorm normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: given as 100mg/m2 IV over days 1 and 8 of each 21 day cycle
Trial: NCT00789867
Drug: pGM169/GL67A
RxNorm normalized name: pGM169/GL67A
DrugBank: pGM169/GL67A (DB17917)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Received a nebulized dose via an breath-actuated nebulizer
Trial: NCT02774902
Drug: TAK-438
RxNorm normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-438 tablets
Trial: NCT01226823
Drug: Ursodeoxycholic Acid
RxNorm normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg capsules 20 mg/kg body weight/day divided in three administrations per day from enrolment until delivery
Trial: NCT02282293
Drug: Monthly dihydroartemisinin-piperaquine (DP) + daily trimethoprim/sulfamethoxazole (TS)
DrugBank: Trimethoprim (DB00440)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02282293
Drug: Monthly placebo + daily trimethoprim/sulfamethoxazole (TS)
DrugBank: Trimethoprim (DB00440)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03927378
Drug: S-ketamine
RxNorm normalized name: S-ketamine
DrugBank: Esketamine (DB11823)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: S-ketamine (0.2 mg/kg in 20 ml normal saline) is administered by intravenous infusion in 40 minutes after childbirth.
Trial: NCT04341727
Drug: Hydroxychloroquine Sulfate
RxNorm normalized name: Hydroxychloroquine Sulfate
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: anti-rheumatic drug (DMARD)
Trial: NCT04341727
Drug: Chloroquine Sulfate
RxNorm normalized name: Chloroquine sulfate
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antimalarial
Trial: NCT00088504
Drug: Merimepodib
RxNorm normalized name: Merimepodib
DrugBank: Merimepodib (DB04862)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00088504
Drug: PEG-Interferon-alpha 2a (Pegasys®)
RxNorm normalized name: Interferon alpha-2a
DrugBank: Interferon alfa-2a (DB00034)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00088504
Drug: Ribavirin (Copegus®)
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04711161
Drug: GRN-300
RxNorm normalized name: methenamine
DrugBank: Methenamine (DB06799)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A salt-inducible kinase (SIK) inhibitor
Trial: NCT04711161
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Microtubule inhibitor
Trial: NCT02449343
Drug: Anlotinib
RxNorm normalized name: Anlotinib
DrugBank: Anlotinib (DB11885)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anlotinib p.o. qd
Trial: NCT01055067
Drug: Tivantinib (ARQ 197)
RxNorm normalized name: Tivantinib
DrugBank: Tivantinib (DB12200)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule, 120 mg, BID (360 mg), approximately 112 days
Trial: NCT02473146
Drug: Gemtuzumab ozogamicin (GO)
RxNorm normalized name: Gemtuzumab Ozogamicin
DrugBank: Gemtuzumab ozogamicin (DB00056)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00831493
Drug: Vorinostat
RxNorm normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Starting Dose of 200 mg orally once daily, Monday to Friday, Weeks 1 to 6.
Trial: NCT01227174
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Procedural sedation will be achieved using propofol
Trial: NCT01550848
Drug: Abraxane and Gemcitabine
RxNorm normalized name: Abraxane
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: ABX (Abraxane) 125 mg/m2，intravenous infusion，30min，day 1, 8, 15~GEM (Gemcitabine) 800 mg/m2，intravenous infusion，30min，day 1, 8, 15
Trial: NCT00022646
Drug: gemcitabine hydrochloride
RxNorm normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00022646
Drug: pemetrexed disodium
RxNorm normalized name: Pemetrexed Disodium
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT01882218
Drug: Galactose
RxNorm normalized name: Galactose
DrugBank: Galactose (DB11735)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After surgery, galactose will be dripped into the belly for up to 24 hours after surgery
Trial: NCT01882218
Drug: Standard Treatment
RxNorm normalized name: Azo-Standard
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard liver surgery.
Trial: NCT00319488
Drug: Inhaled Corticosteroid (Budesonide)
RxNorm normalized name: budesonide Inhalation Suspension
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive inhaled corticosteroid for 7 days, at the first sign of RTI-associated symptoms.
Trial: NCT02298660
Drug: BOTOX
RxNorm normalized name: Botox
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: BOTOX® Total dose per patient: 200U Number of cycles:1 cycle~200 units of BOTOX® will be injected per procedure. BOTOX® will be diluted in 15mL saline to 20U/mL. BOTOX® injections will be performed with a normal 22 FF rigid cystoscopy or flexible 6Fr injection needle. BOTOX® will be injected into the detrusor muscle at 20 sites (10U per site), sparing the trigone. A local anaesthesia with instillation of 50 ml lidocaine 2% into the bladder will be done prior to the procedure to avoid autonomic dysreflexia.
Trial: NCT02121613
Drug: Tamsulosine LP
RxNorm normalized name: LP-20
DrugBank: Tamsulosin (DB00706)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration - 0.4 mg daily.